Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Melanoma is the deadliest form of skin cancer. In the early stages, melanoma can be treated
successfully with surgery alone and survival rates are high, but after metastasis survival …

Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse
effects associated with immune checkpoint blockade can complicate this effective therapy …

The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important
role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However …

Melanoma is one of the most immunologic malignancies based on its higher prevalence in
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …

Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Following their activation and expansion in response to foreign threats, many T cells are
retained in peripheral tissues without recirculating in the blood. These tissue-resident CD8+ …

Background: Melanoma is highly immunogenic and therefore suitable for immunotherapy,
but the efficacy is limited by response rate. In several types of tumor, tumor mutation burden …